Live bacterial vaccines - a review and identification of potential hazards

被引:138
作者
Detmer, Ann [1 ]
Glenting, Jacob
机构
[1] Danish Toxicol Ctr, Horsholm, Denmark
[2] Bioneer AS, Horsholm, Denmark
关键词
D O I
10.1186/1475-2859-5-23
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The use of live bacteria to induce an immune response to itself or to a carried vaccine component is an attractive vaccine strategy. Advantages of live bacterial vaccines include their mimicry of a natural infection, intrinsic adjuvant properties and their possibility to be administered orally. Derivatives of pathogenic and non-pathogenic food related bacteria are currently being evaluated as live vaccines. However, pathogenic bacteria demands for attenuation to weaken its virulence. The use of bacteria as vaccine delivery vehicles implies construction of recombinant strains that contain the gene cassette encoding the antigen. With the increased knowledge of mucosal immunity and the availability of genetic tools for heterologous gene expression the concept of live vaccine vehicles gains renewed interest. However, administration of live bacterial vaccines poses some risks. In addition, vaccination using recombinant bacteria results in the release of live recombinant organisms into nature. This places these vaccines in the debate on application of genetically modified organisms. In this review we give an overview of live bacterial vaccines on the market and describe the development of new live vaccines with a focus on attenuated bacteria and food-related lactic acid bacteria. Furthermore, we outline the safety concerns and identify the hazards associated with live bacterial vaccines and try to give some suggestions of what to consider during their development.
引用
收藏
页数:12
相关论文
共 115 条
[1]   Influenza virus vaccination of patients with SLE: Effects on generation of autoantibodies [J].
Abu-Shakra, M ;
Press, J ;
Sukenik, S ;
Buskila, D .
CLINICAL RHEUMATOLOGY, 2002, 21 (05) :369-372
[2]  
Adachi JA, 2000, J TRAVEL MED, V7, P35
[3]   Oral administration of recombinant Lactococcus lactis expressing bovine β-lactoglobulin partially prevents mice from sensitization [J].
Adel-Patient, K ;
Ah-Leung, S ;
Creminon, C ;
Nouaille, S ;
Chatel, JM ;
Langella, P ;
Wal, JM .
CLINICAL AND EXPERIMENTAL ALLERGY, 2005, 35 (04) :539-546
[4]   Production of human papillomavirus type 16 L1 virus-like particles by recombinant Lactobacillus casei cells [J].
Aires, KA ;
Cianciarullo, AM ;
Carneiro, SM ;
Villa, LL ;
Boccardo, E ;
Pérez-Martinez, G ;
Perez-Arellano, I ;
Oliveira, MLS ;
Ho, PL .
APPLIED AND ENVIRONMENTAL MICROBIOLOGY, 2006, 72 (01) :745-752
[5]   Yersinia enterocolitica as a vehicle for a naked DNA vaccine encoding Brucella abortus bacterioferritin or P39 antigen [J].
Al-Mariri, A ;
Tibor, A ;
Lestrate, P ;
Mertens, P ;
De Bolle, X ;
Letesson, JJ .
INFECTION AND IMMUNITY, 2002, 70 (04) :1915-1923
[6]   No evidence of autoimmunity in 6-year-old children immunized at birth with recombinant hepatitis B vaccine [J].
Belloni, C ;
Avanzini, MA ;
De Silvestri, A ;
Martinetti, M ;
Pasi, A ;
Coslovich, E ;
Autelli, M ;
Masanti, ML ;
Cuccia, M ;
Tinelli, C ;
Rondini, G ;
Lorini, R .
PEDIATRICS, 2002, 110 (01) :e4
[7]   Therapy of mucosal candidiasis by expression of an anti-idiotype in human commensal bacteria [J].
Beninati, C ;
Oggioni, MR ;
Boccanera, M ;
Spinosa, MR ;
Maggi, T ;
Conti, S ;
Magliani, W ;
De Bernardis, F ;
Teti, G ;
Cassone, A ;
Pozzi, G ;
Polonelli, L .
NATURE BIOTECHNOLOGY, 2000, 18 (10) :1060-1064
[8]   Intranasal immunization with recombinant Lactococcus lactis secreting murine interleukin-12 enhances antigen-specific Th1 cytokine production [J].
Bermúdez-Humarán, LG ;
Langella, P ;
Cortes-Perez, NG ;
Gruss, A ;
Tamez-Guerra, RS ;
Oliveira, SC ;
Saucedo-Cardenas, O ;
de Oca-Luna, RM ;
Le Loir, Y .
INFECTION AND IMMUNITY, 2003, 71 (04) :1887-1896
[9]   Dissociation between autoimmune response and clinical disease after vaccination with dendritic cells [J].
Bondanza, A ;
Zimmermann, VS ;
Dell'Antonio, G ;
Dal Cin, E ;
Capobianco, A ;
Sabbadini, MG ;
Manfredi, AA ;
Rovere-Querini, P .
JOURNAL OF IMMUNOLOGY, 2003, 170 (01) :24-27
[10]   Safety and immunogenicity of live recombinant Salmonella enterica serovar Typhi Ty21a expressing urease A and B from Helicobacter pylori in human volunteers [J].
Bumann, D ;
Metzger, WG ;
Mansouri, E ;
Palme, O ;
Wendland, M ;
Hurwitz, R ;
Haas, G ;
Aebischer, T ;
von Specht, BU ;
Meyer, TF .
VACCINE, 2001, 20 (5-6) :845-852